BIOtechNOW featured IVS’s participating BIO Innovation Zone

Later this month in Philadelphia at the BIO International Convention, BIO will be partnering with the National Institutes of Health (NIH) and the National Science Foundation (NSF) to host the 2nd annual, newly-expanded BIO Innovation Zone. The Zone will feature Small Business Innovation Research (SBIR) funded early-stage biotech companies.

Continue reading BIOtechNOW featured IVS’s participating BIO Innovation Zone

BIO Investor Forum Company Snapshot: InvivoSciences

BIO Investor Forum Company Snapshot: InvivoSciences

What is your company’s lead product or technology?

InvivoSciences, Inc. (IVS) is a leading developer of proprietary human 3D cell/tissue culture models for highly-predictive, multi-parameter phenotypic assays both in pharmacology safety & discovery screening and in personalized and regenerative medicine. IVS’s Functional 3D tissue models recapitulate the physiological properties of human cardiac, smooth and skeletal muscle and connective tissue. Application of induced pluripotent technology allows to fabricate tissues in diseased states, e.g., hereditary cardiac diseases, cardiac fibrosis, cancer and orphan diseases. Our unique combination of tissue engineering technology with assay automation and sample miniaturization offers a rapid and cost effective platform for unprecedented therapeutic discovery.

Continue reading BIO Investor Forum Company Snapshot: InvivoSciences

InvivoSciences, Inc. (IVS) is one of the selected companies in NIH’s Innovation Zone at the 2014 BIO International Convention

NIH has partnered with the Biotechnology Industry Organization (BIO) to provide selected SBIR grantees premier visibility at the BIO International Convention. InvivoSciences (IVS) is one of the selected NIH Innovation Zone companies interacting with potential investors and business partners.

BIO International Convention is the world’s largest conference attracting 15,000 biotech leaders from 65 countries. This year the Innovation Zone has been created to showcase NIH and NSF SBIR grantees. Lenka Fedorkova, PhD, program manager for NIH SBIR/STTR programs describes, “Many of today’s largest biotechnology companies, including Amgen, Genzyme and Biogen Idec, received NIH SBIR funding when they were young companies. We are committed to supporting our companies along their path to commercialization and are excited to partner with BIO to showcase the next generation of healthcare market solutions at BIO’s Innovation Zone.”

Contract Research Organization for Drug Discovery